Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALPG | P10696 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461300 | 0.94 | L3MBTL1 (0.50) | LTA4HSMN1; SMN2LMNAALDH1A1ALPG | |
| SCHEMBL5256232 | 0.84 | L3MBTL1 (0.47) | SMN1; SMN2LMNAALDH1A1L3MBTL1ESR2 | |
| SCHEMBL14519387 | 0.84 | L3MBTL1 (0.49) | SMN1; SMN2LMNAALDH1A1ALPGL3MBTL1 | |
| SCHEMBL8836116 | 0.82 | POLB (0.48) | SMN1; SMN2LMNAALDH1A1ALPGHPGD | |
| SCHEMBL8836398 | 0.82 | SMN1; SMN2 (0.43) | LTA4HSMN1; SMN2LMNAALDH1A1ALPG | |
| SCHEMBL27380660 | 0.82 | POLB (0.48) | SMN1; SMN2LMNAALDH1A1ALPGHPGD | |
| SCHEMBL838079 | 0.81 | L3MBTL1 (0.52) | LMNAALDH1A1L3MBTL1ESR2HSD17B10 | |
| SCHEMBL7199609 | 0.81 | LMNA (0.60) | SMN1; SMN2LMNAALDH1A1ALPGL3MBTL1 | |
| SCHEMBL8836254 | 0.81 | HSD17B10 (0.47) | SMN1; SMN2LMNAALDH1A1L3MBTL1ESR2 | |
| SCHEMBL7497934 | 0.80 | SMN1; SMN2 (0.41) | LTA4HSMN1; SMN2LMNAALDH1A1ALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091982-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3091982-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9944648-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944648-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190703-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190703-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-3091982-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326179-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326179-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106158-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-1997033883-A1 | NOVEL PYRIMIDINE COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-18 | — | — | WO | disclosed |
| US-5624931-A | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | disclosed |
| US-5559137-A | PYRAZOLES, ARTHRITIS TREATMENT | SMITHKLINE BEECHAM CORP. (US) | 1996-09-24 | — | — | US | disclosed |
| CN-1120840-A | Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARAMCEUTICAL CO LTD (JP) | 1996-04-17 | — | — | CN | disclosed |
| US-5478827-A | Inhibits Interleukin-1 and tumor necrosis factor production | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0686156-A1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995031451-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5356897-A | Inhibit the production of Interleukin-1 and tumor necrosis factor; administering for treatment of chronic inflammatory diseases, autoimmune diseases and sepsis-induced organ injury | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| WO-1994019350-A1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| EP-0531901-A2 | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190703-A9 | ORGANIC COMPOUNDS | PSEN1, CKMT1A; CKMT1B, GSK3A | LTA4H 2870/4885SMN1; SMN2 645/4885LMNA 1622/4885 |
| US-20160326179-A1 | ORGANIC COMPOUNDS | PSEN1, CKMT1A; CKMT1B, GSK3A | LTA4H 2870/4885SMN1; SMN2 645/4885LMNA 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.